Umar Rafat

Umar Rafat asked about GLP-1 pricing, specifically for orforglipron, and whether recent actions and changes by Lilly's main competitor suggest they might no longer be a 'mature player' from a pricing perspective.

Answer

Lucas Montarce, CFO, noted that Q3 pricing performed as expected, with no significant erosion after the CVS move, aligning with full-year guidance. He emphasized Lilly's commercial and product differentiation, citing Lilly Direct's consistent pricing ($349-$499) and continued market penetration despite competition, indicating no material change in dynamics.

Umar Rafat inquired about GLP-1 pricing, specifically Eli Lilly's orforglipron pricing frameworks, and whether recent actions by a main competitor suggest they will maintain a mature pricing strategy.

Answer

Lucas Montarce, Chief Financial Officer, noted that Q3 pricing performance was as expected, with no significant erosion after the CVS move. He highlighted the stable pricing of Zepbound on Lilly Direct as a benchmark, indicating that market dynamics are not materially changing.